Skip to main content
. 2019 Jul 30;11(8):1078. doi: 10.3390/cancers11081078

Table 4.

Selective ongoing clinical trials of immunotherapy agents in the adjuvant setting.

Targeted Pathways Agents Evaluated Clinical Trial Registration Number
PD-1 + Curative resection Toripalimab NCT03859128
PD-L1 + VEGF + Curative resection or ablation Durvalumab or Durvalumab + bevacizumab NCT03847428
PD-1 + Curative resection or ablation Nivolumab NCT03383458
PD-1 + Curative resection or ablation Pembrolizumab NCT03867084

PD-1: Programmed cell death protein-1; PD-L1: Programmed cell death ligand-1; VEGF: Vascular endothelial growth factor.